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Abstract: Although the total cost of robotic surgery (RS) is known to
be higher than that of laparoscopic surgery (LS), the cost-effectiveness
of RS has not yet been verified. The aim of the study is to clarify the
cost-effectiveness of RS compared with LS for rectal cancer.
From January 2007 through December 2011, 311 and 560 patients
underwent totally RS and conventional LS for rectal cancer, respect-
ively. A propensity score-matching analysis was performed with a ratio
of 1:1 to reduce the possibility of selection bias. Costs and perioperative
short-term outcomes in both the groups were compared. Additional
costs due to readmission were also analyzed.
The characteristics of the patients were not different between the 2
groups. Most perioperative outcomes were not different between the
groups except for the operation time. Complications within 30 days of
surgery were not significantly different. Total hospital charges and
patients’ bill were higher in RS than in LS. The total hospital charges
for patients who recovered with or without complications were higher in
RS than in LS, although their short-term outcomes were similar. In
patients with complications, the postoperative course after RS appeared
to bemilder than that of LS. Total hospital charges for patients whowere
readmitted due to complications were similar between the groups.
RS showed similar short-term outcomes with higher costs than LS.
Therefore, cost-effectiveness focusing on short-term perioperative out-
comes of RS was not demonstrated.
(Medicine 94(22):e823)
Abbreviations: ASA = American Society of Anesthesiologists,
BMI = body mass index, IC = insured charge, LOS = length of stay,PhD, Kang Young ,
MD, PhD, FACSINTRODUCTION
P revious studies have demonstrated that laparoscopic surgery(LS) for colorectal cancer is comparable to open surgery
(OS) in terms of long-term oncologic outcomes and short-term
perioperative outcomes.1–3 Moreover, although robotic surgery
(RS), whichwas introduced only a decade ago, has not been fully
regarded as an alternative surgical option for colorectal cancer, it
has shown not only acceptable short-term outcomes and patho-
logic results but also long-term oncologic outcomes similar to LS
and OS.4–7 Additionally, in attempting to prove the theoretical
advantages of robotic rectal resection (ie, better preservation of
sexual and urinary function), we found evidence supporting the
benefits of this technique in a previous study.8 Based on these
outcomes, robotic rectal surgery is increasing in East Asia and
Western countries. However, the most well-known drawback of
RS is its high cost. Most surgeons in the fields of urology,
gynecology, cardiac surgery, and others have noted higher costs
of RS compared with LS or OS.9–13 Similar data have been
reported by colorectal surgeons, with all investigators who
analyzed the cost of RS for colorectal diseases showing higher
costs of RS compared with LS or OS.14–20 In Korea, patients
who receive RS pay much higher medical fees than patients who
receive OS or LS, due to the unique Korean health care system.
By contrast, there are few studies that have analyzed cost-
effectiveness of RS for colorectal diseases.21 Thus, we analyzed
the cost-effectiveness of RS for rectal cancer focusing on short-
term outcomes within 30 days of surgery compared with LS from
a single large-volume institution in Korea.
METHODS
Patients
From January 2007 through December 2011, a total of 2614
patients underwent low anterior resection for rectal cancer within
15 cm of the anal verge at Severance Hospital, Yonsei University
College of Medicine, Seoul, Korea. Among these patients, 234
who underwent RS were compared with 234 who underwent LS
after propensity score-matching. In this study, the evaluation of
cost-effectiveness was based on the relative correlations between
cost and short-term outcomes.Whether the cost is high or low and
whether the short-term outcomes of RS were good or poor were
rated by relative comparison with LS.
With respect to baseline characteristics, sex, age, body
mass index (BMI), alcohol intake, smoking status, American
Society of Anesthesiologists (ASA) classification, previous
abdominal surgery, neoadjuvant therapy, histology, and tumor
location from the anal verge were evaluated. To evaluatem outcomes, operation type, operation
lood loss, combined resection, ileostomy
to OS, pain score on the day of surgery,
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postoperative day (POD) number 1, and POD number 2, time to
first flatus, time to liquid and soft diet, total and postoperative
length of stay (LOS), morbidity and mortality within 30 days of
surgery, Clavien-Dindo classification of complications,22 and
readmission rates due to complications were evaluated and
compared between the groups. Both robotic and laparoscopic
surgical procedures followed oncologic principles in rectal
cancer surgery. Patients who underwent RS with a hybrid
technique (use of both robotic and laparoscopic instruments)
were excluded. Details of the surgical procedure are described
in our previous studies.5,23 The study was approved by the
institutional review board of Severance Hospital.
Costs
Total hospital chargeswere classified into 2 categories: total
insured charge (IC) and total noninsured charge (NIC). In Korea,
the Korean National Health Insurance Corporation (NHIC), a
government organization, pays 90% of the IC from September
2005 to November 2009, and has paid 95% fromDecember 2009
to the present for patients with cancer for a total of 5 years from
the date of diagnosis. Therefore, the patient’s bill was the sum of
5% or 10% of IC and 100% of NIC in this study. Most treatment
modalities for various diseases are composed of both IC andNIC,
which are decided by theNHIC inKorea.When theNHIC accepts
a certain treatment or medicine as IC, it also determines the cost.
Conversely, when the NHIC names a certain treatment or
medicine as NIC such as additional fee for physician experience
>10 years, private room fees, special diet fees, cost of the new
technology that has not been proven safe with level-1 evidence,
Kim et aland so on, the cost are set by each hospital.
All costs accumulated during admission for RS or LS were
analyzed. Additional costs for readmission due to complications
TABLE 1. Baseline Characteristics of the Patients
Overall Cohort
Variable Robot (n¼ 311) Laparoscopy (n¼ 5
Male 198 (63.9%) 352 (62.9%)
Age, y 57.0 11.5 62.4 10.4
BMI, kg/m2 23.5 2.9 23.3 3.1
Alcohol intake 172 (55.5%) 273 (48.8%)
Smoking 145 (46.8%) 256 (45.7%)
ASA grade
I 84 (27.1%) 98 (17.5%)
II 197 (63.5%) 351 (62.7%)
III 28 (9.0%) 102 (18.2%)
IV 1 (0.3%) 9 (1.6%)
Previous abdominal surgery 52 (16.8%) 114 (20.4%)
Neoadjuvant therapy
Chemotherapy only 8 (2.6%) 7 (1.2%)
Chemoradiotherapy 90 (29.0%) 113 (20.2%)
Tumor location from AV, cm 8.0 3.1 9.3 3.2
Operation year
2007 1 (0.3%) 41 (7.3%)
2008 22 (7.1%) 92 (16.4%)
2009 79 (25.4%) 120 (21.4%)
2010 126 (40.5%) 126 (22.5%)
2011 83 (26.7%) 181 (32.3%)
All values are expressed as meansSDs. ASA¼American Society of A
2 | www.md-journal.comwithin 30 days of surgery were also evaluated. Total hospital
charges were categorized into 5 groups; fees for the operation,
anesthesia, preoperative diagnosis, postoperative management,
and other.
Fees for the operation included surgery and treatment fees
plus the cost of instruments and supplies. Surgery and treatment
fees were composed of the cost of surgery and other treatment
needs including urinary catheter insertion, aseptic dressings,
nasogastric tube insertion, suture removal, and so on. The
surgery fee included the cost for use of the operating room
and compensation for the doctors and nurses who participated in
the surgery. The RS fee was NIC and set at $9756.10, with
consideration of the initial purchasing, maintenance, and depre-
ciation costs of the robotic system. Additionally, the RS fee
included disposable and reusable supplies. On the contrary, the
LS fee was IC and did not include the cost of disposable and
reusable supplies. The LS fee gradually increased from
$1145.30 in January 2007 to $1724.80 in December 2011.
Anesthesia fees were proportional to OT. Fees for pre-
operative diagnosis were composed of the outpatient phys-
ician’s fee, laboratory studies, and imaging study fees. Fees
for postoperative management included cost of the hospital
room, diet, medication, postoperative laboratory studies, ima-
ging studies, transfusion, consultation fees, and other medical
management. Other costs included fees for rehabilitation,
medical documents, and so on.
Statistical Analysis
To reduce the possibility of selection bias, the authors
Medicine  Volume 94, Number 22, June 2015performed propensity score-matching with a ratio of 1:1 accord-
ing to the following 10 variables: year of operation, sex, age,
BMI, alcohol intake, smoking status, ASA classification,
After Matching
60) P Robot (n¼ 251) Laparoscopy (n¼ 251) P
0.770 156 (62.2%) 159 (63.8%) 0.782
<0.001 59.0 11.0 59.1 10.9 0.925
0.502 23.4 2.9 23.5 3.2 0.740
0.066 133 (53.0%) 126 (50.2%) 0.532
0.764 119 (47.4%) 114 (45.4%) 0.655
<0.001 0.929
58 (23.1%) 63 (25.1%)
164 (65.3%) 158 (63.0%)
28 (11.2%) 29 (11.6%)
1 (0.4%) 1 (0.4%)
0.208 47 (18.7%) 46 (18.3%) 0.909
0.001 >0.999
6 (2.4%) 6 (2.4%)
69 (27.5%) 69 (27.5%)
<0.001 8.4 3.2 8.3 3.0 0.885
<0.001 0.451
1 (0.4%) 11 (4.4%)
20 (8.0%) 38 (15.1%)
70 (27.9%) 48 (19.1%)
103 (41.0%) 57 (22.7%)
57 (22.7%) 97 (38.6%)
nesthesiologists; AV¼ anal verge; BMI¼ body mass index.
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previous abdominal surgery, neoadjuvant therapy, and tumor
location. Continuous variables were compared using Student t
tests or Mann–Whitney U test, and categorical variables were
compared using x2 or Fisher exact tests. P values <0.05 were
considered to be statistically significant. All analyses were
performed using Statistical Package for the Social Sciences
(version 20.0, Chicago, IL). All charges were converted to US
dollars according to the May 2014 exchange rate ($1¼ 1025
won).
RESULTS
A total of 871 patients were eligible for participation in this
study. As a result of the propensity score-matching, both groups
included 251 patients, and all variables were balanced. The
baseline characteristics of the patients before and after case-
Medicine  Volume 94, Number 22, June 2015matching are shown in Table 1.
Most perioperative outcomes were similar between the
groups except for the OT (Table 2). The OT was longer in RS
TABLE 2. Perioperative Outcomes and Overall Costs During Adm
Variable Robot (n¼ 25
Operation type
Low anterior resection 210 (83.7%)
Ultra low anterior resection 34 (13.5%)
Intersphincteric resection 7 (2.8%)
Operation time, min 353.1 86.9
Histology
Adenocarcinoma 249 (99.2%)
Tubulovillous adenoma 1 (0.4%)
Carcinoid tumor 0 (0%)
GIST 1 (0.4%)
Estimated blood loss, mL

100 (0–1230
Combined resection 22 (8.8%)
Ileostomy formation 91 (36.3%)
Conversion 0 (0%)
NPIS at
Operation day 4.4 1.6
POD No. 1 3.7 1.3
POD No. 2 3.5 1.3
Time to the first flatus, d 2.8 1.6
Time to liquid diet, d 3.6 2.4
Time to soft diet, d 4.6 2.9
Total length of stay, d 14.2 7.4
Postoperative length of stay, d 10.8 6.0
Morbidity within 30 days of surgery 61 (24.3%)
Readmission within 30 days of surgery 7 (2.8%)
Mortality within 30 days of surgery 0 (0%)
Total hospital charges 15965.10 351
Government’s bill 3352.00 2167
Patient’s bill 12613.10 200
Operation 10375.40 916
Anesthesia 1028.50 257
Preoperative diagnosis 1175.70 1012
Postoperative management 3317.00 2132
Other 56.40 137.2
All values are expressed as meansSDs. Preoperative diagnosis: doc
Postoperative management: room, diet, medication, postoperative laboratory
on; Other: rehabilitation, psychiatry, documents, and so on. GIST¼ gastr
POD¼ postoperative day.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.than in LS, and the time to soft diet was earlier in RS than in LS.
Complications and readmission rates within 30 days of surgery
were not different between the 2 groups.
Total hospital charges were higher in RS than in LS
(Table 2). Operation fees and anesthesia fees were higher in
RS than in LS. Fees for preoperative diagnosis were similar
between the 2 groups. Fees for postoperative management were
not different between the groups.
Comparisons of short-term outcomes and costs between
RS and LS in cases without complications are listed in Table 3.
The RS group had longer OT and higher total hospital charges
than the LS group. Fees for postoperative management were
higher in RS than in LS.
Longer OT and higher total hospital charges in the RS
group than in the LS group were also found in patients with
complications (Table 4). However, the RS group had a shorter
Cost-Effectiveness of Robotic Surgery for Rectal CancerOT during the second operation compared with LS, and a higher
portion of second operations with a borderline P value (0.065).
Anesthesia fees were not different between groups, and fees for
ission ($)
1) Laparoscopy (n¼ 251) P
0.199
218 (86.9%)
31 (12.4%)
2 (0.8%)
266.6 81.8 <0.001
0.145
243 (96.8%)
3 (1.2%)
4 (1.6%)
1 (0.4%)
) 50 (0–3500) 0.817
31 (12.4%) 0.245
79 (31.5%) 0.300
0 (0%) >0.999
4.4 1.4 0.929
3.6 1.2 0.281
3.5 1.3 0.918
3.0 1.7 0.232
3.8 2.1 0.293
4.9 2.9 0.266
14.3 9.4 0.853
11.3 8.7 0.457
57 (22.7%) 0.752
10 (4.0%) 0.623
0 (0%) >0.999
2.10 11933.00 4593.00 <0.001
.90 6829.00 3095.20 <0.001
2.70 5104.00 1903.90 <0.001
.20 6796.30 1347.90 <0.001
.90 875.30 323.40 <0.001
.90 1184.80 1160.90 0.926
.70 3010.20 2342.50 0.126
0 66.50 111.00 0.366
tor’s fee, preoperative laboratory examination and imaging studies;
examination and imaging studies, transfusion, consultation fees, and so
ointestinal submucosal tumor, NPIS¼ numerical pain intensity scale,
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TABLE 3. Comparison of Short-Term Outcomes and Costs Between RS and LS in Cases Without Complications
Robot (n¼ 190) Laparoscopy (n¼ 194) P
Male 114 (60.0%) 114 (58.8%) 0.836
Age, y 58.5 10.9 59.4 11.2 0.396
BMI, kg/m2 23.5 2.8 23.5 3.1 0.833
ASA grade 0.584
I 44 (23.2%) 56 (28.9%)
II 127 (66.8%) 115 (59.3%)
III 19 (10.0%) 22 (11.3%)
IV 0 (0%) 1 (0.5%)
Tumor location from AV, cm 8.3 3.2 8.6 3.1 0.505
Operation time, min 350.6 85.6 256.6 80.1 <0.001
Estimated blood loss, mL

50 (0–1230) 50 (0–3500) 0.975
Combined resection 17 (8.9%) 24 (12.4%) 0.323
Ileostomy formation 65 (34.2%) 60 (30.9%) 0.515
Postoperative length of stay, d 8.7 2.9 8.8 3.2 0.672
Total hospital charges 15138.50 2586.10 10693.00 1815.60 <0.001
Government’s bill 2671.70 1193.00 5982.80 1085.10 <0.001
Patient’s bill 12466.80 1933.10 4710.20 1062.70 <0.001
Operation 10200.20 525.90 6506.10 827.90 <0.001
Anesthesia 974.50 174.70 786.00 152.10 <0.001
Postoperative management 2963.30 1911.90 2416.60 1077.80 0.001
I¼
).
Kim et al Medicine  Volume 94, Number 22, June 2015postoperative management were not different between groups.
Total hospital charges for patients who were readmitted due to
complications within 30 days of surgery were similar between
the 2 groups.
DISCUSSION
Although the short- and long-term outcomes of RS for
rectal cancer are acceptable, the cost of RS is significantly
higher than that of LS or OS. This raises the questions of
whether RS is worthwhile due to its financial burden. In this
study, cost-effectiveness was evaluated focusing on the poten-
tial advantages in short-term outcomes such as early recovery,
lower morbidity during the hospital stay, and adverse events
after discharge for RS compared with LS. Most of the short-
term outcomes were not different except for longer OT in RS. In
terms of complications, the patients who underwent RS
appeared to experience a milder complication, which requires
conservative management than patients who underwent LS.
However, this might be due to the year when the operation
was performed and the increasing use of ‘‘critical pathway,’’
which is a kind of enhanced recovery after surgery program.
Although propensity score-matching was applied so as to
include the year of each operation, LSmay have been performed
earlier than RS. Moreover, the operations included in this study
were performed by 4 surgeons. The learning curves of these
surgeons probably varied, and the effects of this variation were
not assessed. These results show that the high cost of RS was not
compensated for by definitely better perioperative outcomes,
making it difficult to conclude that RS is cost-effective.
Cost-effectiveness is determined by comparing the relative
costs related to outcomes. Because it is difficult to assign a
ASA¼American Society of Anesthesiologists, AV¼ anal verge, BM
All values are expressed as meansSDs except for median (rangemonetary value to measured outcomes or effects on a cost-
effectiveness analysis, there can be various conclusions, which
might be influenced by the investigator’s concerns. Keller
4 | www.md-journal.comet al21 concluded that robotic colorectal resection has higher
costs and longer OT than LS without a measurable benefit
focusing on the perioperative outcomes. Baek et al14 also
showed higher cost of robotic rectal cancer surgery with longer
OT. In other fields, Hohwu et al13 reported that higher costs of
robotic prostatectomy might not be compensated for because
there is no gain in quality-adjusted life-years and the incre-
mental cost-effectiveness ratio using a questionnaire to assess
sexual and voiding functions. However, another urologist group
who used a similar method concluded differently, showing a
gain in quality-adjusted life-years.11 Waters et al12 suggested
that robotic distal pancreatectomy was cost-effective in selected
cases because of comparable direct hospital costs with a shorter
LOS. However, fewer malignancies and greater spleen preser-
vation were observed in their RS than in the LS group,
suggesting that simple cases were selected for RS, and this
selection bias likely resulted in a conclusion favoring RS. In our
study, we defined cost-effectiveness as better short-term out-
comes per similar costs or similar outcomes per lower costs. In
addition, we selected a homogeneous indication and applied a
propensity score-matching analysis to reduce the possibility of
selection bias.
Operation fees resulted in higher total hospital charges in
the RS group compared with the LS group (Table 2). Because
the RS fee was NIC and the LS fee was IC, patients undergoing
RS paid 2.4 times more. Anesthesia fees were higher in the RS
group due to the longer OT compared with that in the LS group.
Fees for preoperative diagnosis were similar because the
diagnostic studies preceding RS and LS were the same. Fees for
postoperative management, however, may reflect the quality of
postoperative outcomes. These costs increased with longer LOS
due to the fees associated with the hospital room, diet, and
body mass index, LS¼ laparoscopic surgery, RS¼ robotic surgery.medications. Among such fees, the use of private rooms, special
diets, and other patient-specific preferences and needs were all
NIC and thus paid by patients. Fees for postoperative
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Comparison of Short-Term Outcomes and Costs Between RS and LS in Cases With Complications
Robot (n¼ 61) Laparoscopy (n¼ 57) P
Male 42 (68.9%) 45 (78.9%) 0.295
Age, y 60.6 11.2 57.9 10.2 0.176
BMI, kg/m2 23.3 3.1 23.5 3.5 0.780
ASA grade 0.652
I 14 (23.0%) 7 (12.3%)
II 37 (60.7%) 43 (75.4%)
III 9 (14.8%) 7 (12.3%)
IV 1 (1.6%) 0 (0%)
Tumor location from AV, cm 8.5 3.3 7.6 2.1 0.079
First operation time, min 360.9 91.4 300.8 78.6 <0.001
Estimated blood loss, mL

180 (0–850) 100 (0–1400) 0.629
Combined resection 5 (8.2%) 7 (12.3%) 0.550
Ileostomy formation 26 (42.6%) 19 (33.3%) 0.346
Postoperative length of stay 17.3 8.3 19.7 14.6 0.287
Clavien–Dindo classification 0.103
I/II/IIIa 38 (62.3%) 27 (47.4%)
IIIb/IV 23 (37.7%) 30 (52.6%)
Treatment for complications 0.065
Conservative management 37 (60.7%) 26 (45.6%)
Second operation during first admission 21 (34.4%) 24 (42.1%)
Second operation during readmission 3 (4.9%) 7 (12.3%)
Second operation time, min 124.0 65.8 198.6 124.7 0.006
Length of stay during readmission 14.7 18.0 12.5 7.1 0.601
Total hospital charges (first operation) 18539.70 4628.80 16153.40 7704.60 0.046
Government’s bill 5874.20 3147.20 10254.10 5213.00 <0.001
Patient’s bill 12946.00 2872.00 6760.00 3273.40 <0.001
Operation 10921.00 1492.20 7783.80 2112.80 <0.001
Anesthesia 1196.80 378.00 1179.10 515.40 0.831
Postoperative management 4418.80 2409.70 5030.50 3888.20 0.311
Total hospital charge (readmission alone) 4974.90 4571.20 4905.90 4116.80 >0.999y
Government’s bill 3502.50 3361.70 3107.30 2772.00 0.922y
Patient’s bill 1472.40 1291.50 1798.60 1518.70 0.536y
I¼
).
Medicine  Volume 94, Number 22, June 2015 Cost-Effectiveness of Robotic Surgery for Rectal Cancermanagement in RS were higher by only $307 (P¼ 0.126) for all
patients. In detail, however, the gap became wider in patients
without complications ($573, P¼ 0.001), and RS resulted in
lower fees for postoperative management in patients with
complications ($612, P¼ 0.311).
Patients without complications, that is, those who had ideal
postoperative courses, had longer OTs and higher costs for RS
than for LS. Higher fees for postoperative management without
any difference of LOS for RS suggested that patients who
underwent RS may have used private rooms or had special
diets. In patients with complications, total hospital charges were
also higher for RS than for LS; however, the gap between them
was reduced to $2386.3, which was less than the overall cost
difference for all patients (Tables 2 and 4). Patients who
underwent LS required a second operation more often than
patients who underwent RS (54.3% vs 39.3%, P¼ 0.065). As a
result, the gap in operation fees between the 2 groups was
reduced to $3137.20 ($10921.00 vs $7783.80, P< 0.001). The
RS group had a shorter OT during the second operation than the
LS group, whereas the OT for the first operation was longer,
ASA¼American Society of Anesthesiologists, AV¼ anal verge, BM
All values are expressed as meansSDs except for median (range
yMann–Whitney U test.which explains why anesthesia fees were similar for both the
groups. Fees for postoperative management were lower in the
RS than in the LS group due to a shorter LOS (17.3 vs 19.7 days,
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.P¼ 0.287). These results suggest that the postoperative course
of the patients who underwent RS might be milder than after LS
in cases in which complications developed, whereas the post-
operative course of the patients who recovered without com-
plications after RS was not different from LS in terms of short-
term outcomes, though with higher associated costs. The fact
that only patients with complications after RS had potential
advantages during recovery is not sufficient to demonstrate the
cost-effectiveness of RS.
Additionally, RS has never been performed as the second
operation in patients with complications after RS or LS as the
first operation. Although RS utilizes advanced techniques that
allow for meticulous dissection andmagnified vision, it is not an
appropriate option for use in an emergent situation due to its
longer OT, lack of tactile sense, and higher costs. In patients
who were readmitted due to complications, all second oper-
ations were OS or LS, which is why total hospital charges
during the readmission period were similar between both the
groups (Table 4).
In this study, RS for rectal cancer did not exhibit remark-
body mass index, LS¼ laparoscopic surgery, RS¼ robotic surgery.able advantages with the exception of the postoperative course
in patients with complications. Therefore, the cost-effectiveness
of RS compared with LS focusing on the short-term outcomes
www.md-journal.com | 5
within 30 days of surgery was not evident. However, these data
are not enough to make a clear conclusion about the cost-
effectiveness of RS because this study only evaluated short-
term outcomes and did not assess postoperative functional
outcomes including sexual and voiding functions. These func-
tional outcomes are important in preserving the quality of life of
the patient. To date, there has been no definitive evidence that
RS results in better functional outcomes than LS.8 Another
limitation of this study is due to the Korean health care system;
thus, the results could not be generalized for the patients in
other countries.
Because the robotic system is a surgical instrument, which
is continuously evolving into future robotic systems may yield
different results. If we consider future clinical trials on the
functional outcomes of RS using more advanced robotic sys-
tems, it is reasonable that the conclusion of this study should be
limited to the current generation robotic system.
Many colorectal surgeons have no experience with RS
because costs for investment and maintenance of the system are
significant, and are arithmetically offset only after approxi-
mately 300 RS cases in Korea. Opportunities for use of RS are
limited to only a few high-volume institutions. If the costs
associated with robotic systems were more reasonable, a larger
pool of data from a larger number of surgeons would be more
widely available.
CONCLUSIONS
The costs of RS were significantly higher than those of LS
for rectal surgery, and short-term outcomes were similar
between RS and LS. Thus, the cost-effectiveness of RS in rectal
surgery was not clear in terms of short-term outcomes. How-
ever, a well-designed future prospective randomized trial that
investigates the cost-effectiveness of RS in terms of functional
outcomes and more advanced robotic systems may yield
different results.
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